What are the recommended guidelines for deep vein thrombosis (DVT) prophylaxis in hospitalized adult or surgical patients?

DVT Prophylaxis Guidelines for Hospitalized and Surgical Patients

All hospitalized medical patients at increased risk for VTE should receive pharmacologic prophylaxis with LMWH, low-dose unfractionated heparin (UFH), or fondaparinux unless they have active bleeding or high bleeding risk, in which case mechanical prophylaxis with intermittent pneumatic compression (IPC) should be used. 1

Risk Stratification is Essential

The American College of Physicians emphasizes that not all hospitalized patients require prophylaxis - you must assess individual VTE risk versus bleeding risk before initiating prophylaxis 2. The evidence does not support universal prophylaxis regardless of risk, and performance measures promoting blanket prophylaxis are inappropriate.

Hospitalized Medical Patients

Pharmacologic Prophylaxis (First-Line)

For acutely ill medical patients at increased risk of thrombosis without bleeding contraindications:

• LMWH (enoxaparin 40 mg SC daily or dalteparin 5,000 units SC daily)
• Low-dose UFH (5,000 units SC every 8 hours - more effective than every 12 hours)
• Fondaparinux (2.5 mg SC daily)

1, 3

Duration: Continue throughout hospitalization or until fully ambulatory. Do not extend prophylaxis beyond hospital discharge in standard medical patients 1, 3.

When Bleeding Risk is High

If patients are actively bleeding or at high risk for major bleeding:

• Use mechanical prophylaxis with IPC (preferred over graduated compression stockings)
• Avoid graduated compression stockings - they are ineffective and cause skin damage 2
• When bleeding risk decreases, switch to pharmacologic prophylaxis 1

Surgical Patients

General and Abdominal-Pelvic Surgery

Risk-stratified approach based on VTE risk (using Caprini or Rogers score):

Moderate Risk (Caprini 3-4):

• LMWH, LDUH, or mechanical prophylaxis with IPC
• Continue for at least 7-10 days 4

High Risk (Caprini ≥5):

• LMWH or LDUH plus mechanical prophylaxis (IPC or elastic stockings)
• Dosing: UFH 5,000 units every 8 hours OR enoxaparin 40 mg daily OR dalteparin 5,000 units daily 4

Cancer Surgery (High Risk):

• Extended-duration prophylaxis for 4 weeks with LMWH after major abdominal or pelvic cancer surgery 5, 6, 7, 4
• This is a strong recommendation (Grade 1B) for patients with high-risk features: restricted mobility, obesity, history of VTE, or residual disease 5, 6

Specific Dosing Regimens for Surgical Patients

Preoperative initiation:

• UFH: 5,000 units 2-4 hours preoperatively, then every 8 hours
• Enoxaparin: 40 mg 10-12 hours preoperatively, then 40 mg daily
• Dalteparin: 5,000 units 10-12 hours preoperatively, then 5,000 units daily
• Fondaparinux: 2.5 mg beginning 6-8 hours postoperatively 5

Cancer Patients - Special Considerations

Hospitalized Cancer Patients

All hospitalized cancer patients should receive pharmacologic prophylaxis unless contraindicated 5, 8, 7. Cancer patients have particularly high VTE risk, and while major trials included only 5-15% cancer patients, the known elevated risk justifies routine prophylaxis 8.

Ambulatory Cancer Patients

Do not routinely use prophylaxis in ambulatory cancer patients receiving chemotherapy 5, 7, 1

Exception: Patients with multiple myeloma receiving thalidomide/lenalidomide-based regimens should receive LMWH or adjusted-dose warfarin (INR 1.5) 5, 7

Do not use prophylaxis for cancer patients with central venous catheters 1

Critically Ill Patients

For ICU patients, use LMWH or LDUH over no prophylaxis 1. If bleeding risk is high, use mechanical prophylaxis (IPC preferred) until bleeding risk decreases, then switch to pharmacologic prophylaxis 1.

Key Contraindications and Caveats

Absolute Contraindications to Pharmacologic Prophylaxis:

• Active bleeding
• High risk for major bleeding
• Severe thrombocytopenia
• Recent neurosurgery or spinal procedures (timing considerations for neuraxial anesthesia) 5

Important Warnings:

Neuraxial anesthesia: When epidural/spinal anesthesia is planned, LMWH should not be given within 10-12 hours before the procedure. After catheter removal, wait at least 2 hours before administering LMWH 5.

Renal impairment: Adjust LMWH doses (particularly enoxaparin, dalteparin, tinzaparin) in patients with creatinine clearance <30 mL/min 5.

Heparin-induced thrombocytopenia: LMWH has lower risk than UFH (1/1900 vs 7/1900 cases) 2.

Agent Selection

Choice between LMWH, UFH, and fondaparinux should be based on:

• Ease of administration (daily vs. multiple daily dosing)
• Cost (UFH ~$10/day, LMWH ~$35/day, fondaparinux ~$60/day)
• Renal function
• Bleeding risk profile 2

LMWH is generally preferred for surgical cancer patients over UFH based on guideline recommendations 6, 7.

What NOT to Do

• Do not use graduated compression stockings alone - they are ineffective and cause skin damage 2
• Do not extend prophylaxis beyond hospital discharge in standard medical patients 1, 3
• Do not use routine prophylaxis in low-risk patients, chronically immobilized nursing home residents, or long-distance travelers (unless very high risk) 1
• Do not use aspirin as primary VTE prophylaxis 1